|

BCL-2 inhibitors combined with the HyperCVAD regimen Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1

Indications

  • Lymphoblastic Leukemia, Acute T-cell1
  • Lymphoblastic Lymphoma, Adult1
  • Cancer1

Other1 trial

BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.